Michael Esposito
Vice President, Finance
, Massachusetts, United States
Professional Overview
Michael Esposito is an experienced finance executive with a strong track record of leadership and strategic contributions in the biopharmaceutical industry. As the Vice President of Finance at Arkuda Therapeutics, he oversees all financial operations and planning to drive the company's growth and success.
Experience Summary
Current Role
As Vice President of Finance at Arkuda Therapeutics, Michael is responsible for managing the company's financial affairs, including forecasting, budgeting, reporting, and compliance. He works closely with the executive team to align financial strategies with Arkuda's business objectives, supporting the development and commercialization of innovative therapies.
Career Progression
Prior to his current role, Michael served as the Executive Director and Controller at CRISPR Therapeutics, where he played a pivotal role in the company's financial operations and scaling initiatives. He has also held senior finance positions at FORUM Pharmaceuticals, Aarvon Biosciences, and Baxter Healthcare, demonstrating a diverse background in the pharmaceutical and biotech sectors.
Michael began his career as a Supervisor at KPMG Peat Marwick, gaining valuable experience in public accounting and financial reporting. His extensive industry experience and leadership skills have enabled him to make significant contributions to the companies he has served.
Academic Background
Michael holds a Bachelor's degree in Accounting from a leading university, providing him with a strong foundation in financial management and reporting.
Areas of Expertise
- Financial planning and analysis
- Budgeting and forecasting
- Accounting and compliance
- Financial reporting and control
- Strategic financial decision-making
- Leadership and team management
Professional Impact
During his tenure at CRISPR Therapeutics, Michael played a crucial role in the company's rapid growth and expansion, overseeing the finance function and ensuring the successful execution of complex financial initiatives. His contributions were instrumental in supporting the development and advancement of CRISPR's pipeline of gene-editing therapies.
Conclusion
With his extensive finance expertise, industry knowledge, and proven leadership abilities, Michael Esposito is well-positioned to drive Arkuda Therapeutics' financial strategy and contribute to the company's long-term success. His commitment to excellence and collaborative approach make him a valuable asset to the organizations he serves.
